SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
---------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August 3, 1998
SYNAPTIC PHARMACEUTICAL CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
0-27324 22-285-9704
(Commission File Number) (I.R.S. Employer Identification No.)
215 College Road
Paramus, New Jersey 07652-1431
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (201) 261-1331
Page 1 of 3 Pages
<PAGE>
Item 5. Other Events
On August 3, 1998, the term of the Company's collaboration with
Novartis, which was focused principally on the identification and development of
neuropeptide Y drugs for the treatment of obesity and eating disorders, as well
as cardiovascular disorders, expired in accordance with the terms of the
Research and License Agreement dated as of August 4, 1994, as amended, and the
Research and License Agreement dated as of May 31, 1996. In connection with the
expiration of the collaboration, Novartis' obligation to provide the Company
with funding to support a specified number of the Company's scientists
terminated. Novartis continues to have a license under certain patent rights and
to certain technology of the Company pursuant to the terms of the Research and
License Agreements.
Page 2 of 3 Pages
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: August 3, 1998
SYNAPTIC PHARMACEUTICAL CORPORATION
(Registrant)
By:/s/Kathleen P. Mullinix
-------------------------------------------
Name: Kathleen P. Mullinix
Title: Chairman, President and
Chief Executive Officer
Page 3 of 3 Pages
